HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML
Chin K, Derkach A, Famulare C, Gupta G, Borge P, Geyer M, Goldberg A, Haque T, Park J, Roeker L, Tallman M, Stahl M, Stein E. HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML. Blood 2024, 144: 5962-5962. DOI: 10.1182/blood-2024-211733.Peer-Reviewed Original ResearchAcute myeloid leukemiaMedian overall survivalIsocitrate dehydrogenase-mutantCommon Terminology Criteria for Adverse EventsMeasurable residual diseaseOverall survivalTreatment modificationNo significant differenceCR/CRi rateMRD negativityHypomethylating agentsSignificant differenceLong-term survival outcomesSingle-center retrospective studyToxicity associated with treatmentMutant acute myeloid leukemiaCycle lengthChemotherapy-ineligible patientsGrade 3 neutropeniaMRD-negativity ratesTreatment cycle characteristicsAssociated with higher responseEvent-free survivalKaplan-Meier methodologyEfficacious treatment regimensHow Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
Kura K, Stolk W, Basáñez M, Collyer B, de Vlas S, Diggle P, Gass K, Graham M, Hollingsworth T, King J, Krentel A, Anderson R, Coffeng L. How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis? Clinical Infectious Diseases 2024, 78: s93-s100. PMID: 38662701, PMCID: PMC11045024, DOI: 10.1093/cid/ciae021.Peer-Reviewed Original ResearchConceptsMass drug administrationElimination of lymphatic filariasisEfficacious treatment regimensLymphatic filariasisLevels of NTMass drug administration programmesYears of annual treatmentTreatment regimensDrug combinationsTransmission settingsMass drug administration programsDrug AdministrationTreatment coveragePrevalenceTransmission areasMDA coverageBaselineProportion of peopleTreatmentPrevalence thresholdImpact of NTAlbendazoleDiethylcarbamazineHighest infection prevalenceHighest proportion
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply